Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension
(PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is …

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and can complicate the majority of cardiovascular and respiratory …

6.2. 2. Wydolność wysiłkowa......................... 1147 6.2. 3. Markery biochemiczne........................
1147 6.2. 4. Kompleksowa ocena rokownicza i oszacowanie ryzyka........................... 1148 6.2 …

Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Background In a phase 2 trial, selexipag, an oral selective IP prostacyclin-receptor agonist,
was shown to be beneficial in the treatment of pulmonary arterial hypertension. Methods In …

Pulmonary hypertension is associated with diverse cardiac, pulmonary, and systemic
diseases in neonates, infants, and older children and contributes to significant morbidity and …

Background Data on the effect of initial combination therapy with ambrisentan and tadalafil
on long-term outcomes in patients with pulmonary arterial hypertension are scarce. Methods …

In the past 2 decades, major changes have occurred in the epidemiological and treatment
landscape of pulmonary arterial hypertension (PAH). Previously regarded as a disease of …

Background Current therapies for pulmonary arterial hypertension have been adopted on
the basis of short-term trials with exercise capacity as the primary end point. We assessed …